189 related articles for article (PubMed ID: 37004703)
21. Long-term effectiveness and safety of lacosamide as adjunctive therapy in children and adolescents with refractory epilepsy: a real-world study.
Zhao T; Yu LH; Zhang HL; Yu J; Feng J; Wang TT; Sun Y; Li HJ
BMC Pediatr; 2023 May; 23(1):249. PubMed ID: 37210552
[TBL] [Abstract][Full Text] [Related]
22. Lacosamide efficacy and tolerability in clinical practice - Post marketing analysis from a single dedicated epilepsy center.
Baker MD; Abou-Khalil BW; Arain A; Tummala P; Azar NJ; Haas KF; Sonmezturk HH
Clin Neurol Neurosurg; 2018 Aug; 171():179-183. PubMed ID: 29929174
[TBL] [Abstract][Full Text] [Related]
23. Lacosamide in monotherapy in BTRE (brain tumor-related epilepsy): results from an Italian multicenter retrospective study.
Mo F; Meletti S; Belcastro V; Quadri S; Napolitano M; Bello L; Dainese F; Scarpelli M; Florindo I; Mascia A; Pauletto G; Bruno F; Pellerino A; Giovannini G; Polosa M; Sessa M; Conti Nibali M; Di Gennaro G; Gigli GL; Pisanello A; Cavallieri F; Rudà R
J Neurooncol; 2022 May; 157(3):551-559. PubMed ID: 35397759
[TBL] [Abstract][Full Text] [Related]
24. Early clinical experience with lacosamide as adjunctive therapy in patients with refractory focal epilepsy and nocturnal seizures.
García-Morales I; Delgado RT; Falip M; Campos D; García ME; Gil-Nagel A
Seizure; 2011 Dec; 20(10):801-4. PubMed ID: 21917484
[TBL] [Abstract][Full Text] [Related]
25. Long-term efficacy of add-on lacosamide treatment in children and adolescents with refractory epilepsies: A single-center observational study.
Rosati A; Ilvento L; Rizzi R; Doccini V; Leo MC; Pugi A; De Masi S; Guerrini R
Epilepsia; 2018 May; 59(5):1004-1010. PubMed ID: 29663335
[TBL] [Abstract][Full Text] [Related]
26. [Russian experience of lacosamide (vimpat) usage in treatment of uncontrolled focal epilepsy].
Lebedeva AV; Burd SG; Belyaev OV; Vlasov PN; Dorofeeva MY; Ismailov AM; Kissin MY; Kovaleva IY; Koroleva NY; Lipatova LV; Mukhin KY; Solomatin YV; Chervyakov AV; Shikhkerimov RG; Pylaeva OA; Freidkova NV
Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(9. Vyp. 2):74-81. PubMed ID: 28005051
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and tolerability of treatment with lacosamide in children: Postmarketing experience from the Middle East.
Hmaimess G; Sabbagh S; Dirani M; Hotait M; Beydoun AA; Nasreddine W
Seizure; 2020 Jul; 79():75-79. PubMed ID: 32422546
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of lacosamide in infants and young children with refractory focal epilepsy.
Grosso S; Parisi P; Spalice A; Verrotti A; Balestri P
Eur J Paediatr Neurol; 2014 Jan; 18(1):55-9. PubMed ID: 24129195
[TBL] [Abstract][Full Text] [Related]
29. Safety and tolerability of lacosamide as adjunctive therapy for adults with partial-onset seizures: Analysis of data pooled from three randomized, double-blind, placebo-controlled clinical trials.
Biton V; Gil-Nagel A; Isojarvi J; Doty P; Hebert D; Fountain NB
Epilepsy Behav; 2015 Nov; 52(Pt A):119-27. PubMed ID: 26414341
[TBL] [Abstract][Full Text] [Related]
30. A noninterventional study evaluating the effectiveness and safety of lacosamide added to monotherapy in patients with epilepsy with partial-onset seizures in daily clinical practice: The VITOBA study.
Runge U; Arnold S; Brandt C; Reinhardt F; Kühn F; Isensee K; Ramirez F; Dedeken P; Lauterbach T; Noack-Rink M; Mayer T
Epilepsia; 2015 Dec; 56(12):1921-30. PubMed ID: 26526971
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and tolerability of brivaracetam compared to lacosamide, eslicarbazepine acetate, and perampanel as adjunctive treatments in uncontrolled focal epilepsy: Results of an indirect comparison meta-analysis of RCTs.
Brigo F; Bragazzi NL; Nardone R; Trinka E
Seizure; 2016 Nov; 42():29-37. PubMed ID: 27710868
[TBL] [Abstract][Full Text] [Related]
32. Effect of lacosamide on depression and anxiety symptoms in patients with focal refractory epilepsy: A prospective multicenter study.
Rocamora R; Ley M; Molins A; Toledo M; Sansa G; Bertol V; Becerra JL; Carreño M; Mauri JÁ
Epilepsy Behav; 2018 Feb; 79():87-92. PubMed ID: 29253680
[TBL] [Abstract][Full Text] [Related]
33. Clinical outcomes of perampanel vs. lacosamide in cohorts of consecutive patients with severely refractory epilepsies - A monocentric retrospective analysis of systematically collected data from the German Kork Epilepsy Center.
Kurth C; Kockelmann E; Steinhoff BJ
Seizure; 2017 Feb; 45():47-51. PubMed ID: 27915111
[TBL] [Abstract][Full Text] [Related]
34. Clinical impact of the dose and blood concentration of lacosamide in Japanese pediatric patients with epilepsy: A cohort study.
Ishikawa N; Eguchi Y; Izumo H; Tateishi Y; Tani H; Kobayashi Y; Okada S
Epilepsy Behav; 2022 Apr; 129():108614. PubMed ID: 35203014
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and tolerability of lacosamide and controlled-release carbamazepine monotherapy in patients with newly diagnosed temporal lobe epilepsy: Post hoc analysis of a randomized, double-blind trial.
Terada K; Kubota Y; Dimova S; Elmoufti S; Floricel F; Chellun D; O'Brien TJ
Seizure; 2023 Nov; 112():62-67. PubMed ID: 37769545
[TBL] [Abstract][Full Text] [Related]
36. LACONORTE study: Efficacy and security of lacosamide as first add-on therapy for focal-onset epilepsy in real-life setting.
Muñoz-Lopetegi A; López-González FJ; Rodríguez-Osorio X; Pato Pato A; Bellas Lamas P; Abella-Corral J; Castro Vilanova MD; Garea MJ; Gil López JA; Ruiz-Martínez J; Poza JJ
Epilepsy Res; 2018 Sep; 145():51-54. PubMed ID: 29890341
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and tolerability of adjunctive lacosamide in patients aged <4 years with focal seizures.
Makedonska I; Ng YT; Beller C; Bozorg A; Csikós J; McClung C; Moeltgen H; Farkas MK;
Ann Clin Transl Neurol; 2024 Mar; 11(3):768-779. PubMed ID: 38375995
[TBL] [Abstract][Full Text] [Related]
38. Use of lacosamide in children: experience of a tertiary medical care center in Brazil.
Romão TT; Angelim AIM; Prado HJPD; Goes FV; Pires MEP; Fontana RDS; Pires LC; Fernandes AR; D'Andrea-Meira I
Arq Neuropsiquiatr; 2022 Nov; 80(11):1090-1096. PubMed ID: 36577407
[TBL] [Abstract][Full Text] [Related]
39. Value of drug level concentrations of brivaracetam, lacosamide, and perampanel in care of people with epilepsy.
Hentschel M; Stoffel-Wagner B; Surges R; von Wrede R; Dolscheid-Pommerich RC
Epilepsia; 2024 Mar; 65(3):620-629. PubMed ID: 38158709
[TBL] [Abstract][Full Text] [Related]
40. Final safety, tolerability, and seizure outcomes in patients with focal epilepsy treated with adjunctive perampanel for up to 4 years in an open-label extension of phase III randomized trials: Study 307.
Krauss GL; Perucca E; Kwan P; Ben-Menachem E; Wang XF; Shih JJ; Patten A; Yang H; Williams B; Laurenza A
Epilepsia; 2018 Apr; 59(4):866-876. PubMed ID: 29574701
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
